6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Capturing Differential Allele-Level Expression and Genotypes of All Classical HLA Loci and Haplotypes by a New Capture RNA-Seq Method

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The highly polymorphic human major histocompatibility complex (MHC) also known as the human leukocyte antigen (HLA) encodes class I and II genes that are the cornerstone of the adaptive immune system. Their unique diversity (>25,000 alleles) might affect the outcome of any transplant, infection, and susceptibility to autoimmune diseases. The recent rapid development of new next-generation sequencing (NGS) methods provides the opportunity to study the influence/correlation of this high level of HLA diversity on allele expression levels in health and disease. Here, we describe the NGS capture RNA-Seq method that we developed for genotyping all 12 classical HLA loci ( HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4 , and HLA-DRB5) and assessing their allelic imbalance by quantifying their allele RNA levels. This is a target enrichment method where total RNA is converted to a sequencing-ready complementary DNA (cDNA) library and hybridized to a complex pool of RNA-specific HLA biotinylated oligonucleotide capture probes, prior to NGS. This method was applied to 161 peripheral blood mononuclear cells and 48 umbilical cord blood cells of healthy donors. The differential allelic expression of 10 HLA loci (except for HLA-DRA and HLA-DPA1) showed strong significant differences ( P < 2.1 × 10 −15). The results were corroborated by independent methods. This newly developed NGS method could be applied to a wide range of biological and medical questions including graft rejections and HLA-related diseases.

          Related collections

          Most cited references52

          • Record: found
          • Abstract: found
          • Article: not found

          Influence of HLA-C expression level on HIV control.

          A variant upstream of human leukocyte antigen C (HLA-C) shows the most significant genome-wide effect on HIV control in European Americans and is also associated with the level of HLA-C expression. We characterized the differential cell surface expression levels of all common HLA-C allotypes and tested directly for effects of HLA-C expression on outcomes of HIV infection in 5243 individuals. Increasing HLA-C expression was associated with protection against multiple outcomes independently of individual HLA allelic effects in both African and European Americans, regardless of their distinct HLA-C frequencies and linkage relationships with HLA-B and HLA-A. Higher HLA-C expression was correlated with increased likelihood of cytotoxic T lymphocyte responses and frequency of viral escape mutation. In contrast, high HLA-C expression had a deleterious effect in Crohn's disease, suggesting a broader influence of HLA expression levels in human disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Regulation of MHC class II gene expression by the class II transactivator.

            MHC class II molecules are pivotal for the adaptive immune system, because they guide the development and activation of CD4+ T helper cells. Fulfilling these functions requires that the genes encoding MHC class II molecules are transcribed according to a strict cell-type-specific and quantitatively modulated pattern. This complex gene-expression profile is controlled almost exclusively by a single master regulatory factor, which is known as the class II transactivator. As we discuss here, differential activation of the three independent promoters that drive expression of the gene encoding the class II transactivator ultimately determines the exquisitely regulated pattern of MHC class II gene expression.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Genetic control of MHC class II expression.

              The presentation of peptides to T cells by MHC class II molecules is of critical importance in specific recognition by the immune system. Expression of class II molecules is exquisitely controlled at the transcriptional level. A large set of proteins interact with the promoters of class II genes. The most important of these is CIITA, a master controller that orchestrates expression but does not bind directly to the promoter. The transcriptosome complex formed at class II promoters is a model for induction of gene expression.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                29 May 2020
                2020
                : 11
                : 941
                Affiliations
                [1] 1Department of Pathology, Stanford University School of Medicine , Palo Alto, CA, United States
                [2] 2Department of Molecular Life Science, Tokai University School of Medicine , Isehara, Japan
                [3] 3Faculty of Health and Medical Science, Teikyo Heisei University, Toshima-ku , Tokyo, Japan
                [4] 4Division of Hematopoietic Cell Transplantation, Department of Innovative Medical Science, Tokai University School of Medicine , Isehara, Japan
                [5] 5Histocompatibility, Immunogenetics, and Disease Profiling Laboratory, Stanford Blood Center, Stanford Health Care , Palo Alto, CA, United States
                [6] 6Department of Hematology and Oncology, Nagoya University Graduate School of Medicine , Nagoya, Japan
                [7] 7Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus , Nishihara, Japan
                [8] 8Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine , Nagakute, Japan
                [9] 9Faculty of Health and Medical Sciences, The University of Western Australia Medical School , Crawley, WA, Australia
                [10] 10Laboratoire d'ImmunoRhumatologie Moléculaire, Plateforme GENOMAX, INSERM UMR_S 1109, LabEx TRANSPLANTEX, Fédération Hospitalo-Universitaire OMICARE, Laboratoire International Associé INSERM FJ-HLA-Japan, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Faculté de Médecine, Université de Strasbourg, Service d'Immunologie Biologique, Nouvel Hôpital Civil , Strasbourg, France
                Author notes

                Edited by: Martin Maiers, National Marrow Donor Program, United States

                Reviewed by: Pietro Crivello, Essen University Hospital, Germany; Marco Andreani, Bambino Gesù Ospedale Pediatrico (IRCCS), Italy

                *Correspondence: Takashi Shiina tshiina@ 123456is.icc.u-tokai.ac.jp

                This article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in Immunology

                †These authors have contributed equally to this work

                Article
                10.3389/fimmu.2020.00941
                7272581
                32547543
                5513bb6e-cb9e-4c02-8c53-5f9627b3759c
                Copyright © 2020 Yamamoto, Suzuki, Mizutani, Shigenari, Ito, Kametani, Kato, Fernandez-Viña, Murata, Morishima, Morishima, Tanaka, Kulski, Bahram and Shiina.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 03 December 2019
                : 22 April 2020
                Page count
                Figures: 3, Tables: 2, Equations: 0, References: 65, Pages: 14, Words: 10629
                Funding
                Funded by: Ministry of Education, Culture, Sports, Science and Technology 10.13039/501100001700
                Funded by: Japan Agency for Medical Research and Development 10.13039/100009619
                Funded by: Agence Nationale de la Recherche 10.13039/501100001665
                Funded by: Merck Sharp and Dohme 10.13039/100009947
                Categories
                Immunology
                Original Research

                Immunology
                human leukocyte antigen,next-generation sequencing,hla allele,rna expression level,genotyping,capture rna-seq

                Comments

                Comment on this article